Opendata, web and dolomites

SVNanoVax SIGNED

Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SVNanoVax project word cloud

Explore the words cloud of the SVNanoVax project. It provides you a very rough idea of what is the project "SVNanoVax" about.

quality    sequence    scarselli    protective    generation    fhbp    self    structural    assembling    2014    lives    potentiate    vaccine    invasive    immunogenic    disease    vaccines    ryan    suitable    safety    bexsero    bionanoparticle    million    copy    bactericidal    map    combines    epitope    meningococcal    save    2nd    bnps    3d    reducing    enhanced    expertise    vaccinology    protein    displaying    ordered    bnp    antigen    secondly    broadly    infectious    delany    promises    protect    career    stably    menb    diseases    bionanoparticles    functional    sepsis    structures    variability    candidates    immunogenicity    pace    serogroup    generate    arrays    approved    encompassing    structure    prepared    meningitidis    bachmann    optimized    escape    2010    coverage    breadth    2013    nanobiology    mapping    termed    neisseria    host    pioneered    opportunity    overcome    issue    1st    monoclonal    2012    firstly    antibodies    innovative    nada    safe    antigens    humans    combine    epitopes    offers    malito    display    2011    probability    pathogens    aid   

Project "SVNanoVax" data sheet

The following table provides information about the project.

Coordinator
GLAXOSMITHKLINE VACCINES SRL 

Organization address
address: VIA FIORENTINA 1
city: SIENA
postcode: 53100
website: www.novartis.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 168˙277 €
 EC max contribution 168˙277 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2015
 Duration (year-month-day) from 2015-06-15   to  2017-06-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLAXOSMITHKLINE VACCINES SRL IT (SIENA) coordinator 168˙277.00

Map

 Project objective

Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A key issue for future vaccines is how to improve immunogenicity without reducing safety (Bachmann, 2010). Another challenge is that high antigen sequence variability enables pathogens to escape the host response. To overcome these challenges, this proposal combines Structural Vaccinology and bionanoparticle (BNP) design, to generate novel self-assembling BNPs with multi-copy antigen display for the development of safe vaccine antigens with enhanced immunogenicity and breadth of coverage.

We will generate antigen-BNPs for a 2nd generation vaccine against Neisseria meningitidis serogroup B (MenB), a major cause of sepsis and invasive disease (Pace, 2012). This research may also potentiate antigen-BNP technology suitable for other vaccines. Firstly, we will use functional (bactericidal) monoclonal antibodies to map the most protective epitopes on the 3D structures of two key MenB antigens, fHbp and NadA, which contribute strongly to our recently-approved 1st generation MenB vaccine, Bexsero (O’Ryan, 2014). To aid this, we have developed wide expertise in structure-focused epitope mapping (Malito, 2013). Secondly, we will design optimized antigens stably displaying the best epitopes, an approach that we have pioneered and termed ‘Structural Vaccinology’ (Scarselli, 2011). Finally, self-assembling protein bionanoparticles displaying ordered arrays of the optimized antigens will be prepared, in order to generate novel highly-immunogenic, broadly-protective MenB vaccine candidates.

The proposal offers an exciting career development opportunity encompassing novel high-quality research to combine and deliver the promises of Structural Vaccinology and nanobiology, with a high probability of success to generate innovative new vaccine antigens for products to protect humans against meningococcal and other infectious diseases.

 Publications

year authors and title journal last update
List of publications.
2016 Jacinto López-Sagaseta, Enrico Malito, Rino Rappuoli, Matthew J. Bottomley
Self-assembling protein nanoparticles in the design of vaccines
published pages: 58-68, ISSN: 2001-0370, DOI: 10.1016/j.csbj.2015.11.001
Computational and Structural Biotechnology Journal 14 2019-06-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SVNANOVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SVNANOVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

DEF2DEV (2019)

Identification of the mode of action of plant defensins during root development and plant defense responses.

Read More  

CREDit (2020)

Chronological REference Datasets and Sites (CREDit) towards improved accuracy and precision in luminescence-based chronologies

Read More  

EngPTC2 (2019)

Exploring new technologies for the next generation pulse tube cryocooler below 2K

Read More